TSHA-102 Gene Therapy Trial in Rett Syndrome: Second Patient Dosing is Recommended.

Published Date: 06 Aug 2023

Taysha Gene Therapies was encouraged to carry out further research into the therapy in a second patient after the first patient who received TSHA-102, an adeno-associated virus vector-based gene therapy for Rett syndrome, experienced success.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

More Positive Survival Data in Lung Cancer With Perioperative Therapy

2.

Upfront TKI for Bone-Predominant RCC Tops Single-Agent Immunotherapy

3.

Study finds 10% of pediatric blood cancers may stem from medical imaging radiation

4.

For the creation of cutting-edge targeted radionuclide therapies in oncology, Bayer and Bicycle Therapeutics work together.

5.

Pre-operative evaluation of ovarian cancer patients using DWI-MRI is helpful.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot